Retrieve available abstracts of 17 articles: HTML format
Single Articles
April 2025
SMITH-JACKSON K, Walsh P, Zelek WM, Hoyler T, et al The membrane attack complex drives thrombotic microangiopathy in complement
mediated atypical hemolytic uremic syndrome.
Kidney Int. 2025;107:700-713. PubMedAbstract available
December 2024
KAVANAGH D, Ardissino G, Brocklebank V, Bouwmeester RN, et al Outcomes from the International Society of Nephrology Hemolytic Uremic Syndromes
International Forum.
Kidney Int. 2024;106:1038-1050. PubMedAbstract available
September 2024
NESTER CM, Feldman DL, Burwick R, Cataland S, et al An expert discussion on the atypical hemolytic uremic syndrome
nomenclature-identifying a road map to precision: a report of a National Kidney
Foundation Working Group.
Kidney Int. 2024;106:326-336. PubMedAbstract available
VIVARELLI M, Barratt J, Beck LH Jr, Fakhouri F, et al The role of complement in kidney disease: conclusions from a Kidney Disease:
Improving Global Outcomes (KDIGO) Controversies Conference.
Kidney Int. 2024;106:369-391. PubMedAbstract available
August 2024
WILLICOMBE M, Roberts DJ TRANSFUSION-INDUCED HLA SENSITISATION IN WAITLIST PATIENTS AND KIDNEY TRANSPLANT
RECIPIENTS.
Kidney Int. 2024 Aug 22:S0085-2538(24)00573-8. doi: 10.1016/j.kint.2024. PubMedAbstract available
May 2024
MAISONS V, Duval A, Mesnard L, Frimat M, et al Assessment of epidemiology and outcomes of adult patients with kidney-limited
thrombotic microangiopathies.
Kidney Int. 2024;105:1100-1112. PubMedAbstract available
CHE M, Moran SM, Smith RJ, Ren KYM, et al A case-based narrative review of pregnancy-associated atypical hemolytic uremic
syndrome/complement-mediated thrombotic microangiopathy.
Kidney Int. 2024;105:960-970. PubMedAbstract available
April 2024
CORNELL LD, Shankaranarayanan D, Rodriguez PS, Damgard SE, et al Sickle cell disease in the kidney transplant.
Kidney Int. 2024;105:892. PubMed
February 2024
ZHANG Y, Martin B, Spies MA, Roberts SM, et al Renin and renin blockade have no role in complement activity.
Kidney Int. 2024;105:328-337. PubMedAbstract available
January 2024
KAARTINEN K, Schenk P, Raisanen-Sokolowski A, Dunkel J, et al The Case | Refractory anemia in a patient undergoing dialysis.
Kidney Int. 2024;105:211-212. PubMed
October 2023
HUERTA A, Arjona E, Portoles J, Lopez-Sanchez P, et al On the relevance of thrombomodulin variants in atypical hemolytic uremic
syndrome.
Kidney Int. 2023;104:851-855. PubMed
September 2023
ECKARDT KU, Kurtz A Secrets and myths between tubules - new insights on erythropoietin production
from single cell technology.
Kidney Int. 2023 Sep 13:S0085-2538(23)00634-8. doi: 10.1016/j.kint.2023. PubMed
August 2023
LABOUX T, Maanaoui M, Allain F, Boulanger E, et al Hemolysis is associated with altered heparan sulfate of the endothelial
glycocalyx and with local complement activation in thrombotic microangiopathies.
Kidney Int. 2023;104:353-366. PubMedAbstract available
July 2023
KOURY MJ, Haase VH Deregulating iron-erythropoiesis regulation: transferrin receptor 2 as potential
target for treating anemia in CKD.
Kidney Int. 2023;104:25-28. PubMedAbstract available
June 2023
LOCATELLI F, Del Vecchio L Quality of life: a crucial aspect for the patients, a neglected goal in the
treatment of anemia in patients with CKD.
Kidney Int. 2023;103:1025-1027. PubMedAbstract available
May 2023
KU E, Del Vecchio L, Eckardt KU, Haase VH, et al Novel Anemia Therapies in CKD: Conclusions from a Kidney Disease: Improving
Global Outcomes (KDIGO) Controversies Conference.
Kidney Int. 2023 May 24:S0085-2538(23)00379-4. doi: 10.1016/j.kint.2023. PubMedAbstract available
March 2023
OLIVARI V, Di Modica SM, Lidonnici MR, Aghajan M, et al A single approach to targeting transferrin receptor 2 corrects iron and
erythropoietic defects in murine models of anemia of inflammation and chronic
kidney disease.
Kidney Int. 2023 Mar 27:S0085-2538(23)00179-5. doi: 10.1016/j.kint.2023. PubMedAbstract available